To look at the biology of kidney cancer, the trial team need tumour tissue samples and blood samples from patients with kidney cancer. Patients cannot be identified from these samples (they are anonymised samples). Using these samples, the researchers can look at the biology of kidney cancer, such as the structure of kidney cancer cells under a microscope, genetics, and the action of the immune system.

The aim of the study is to understand what drives the growth of kidney cancer. This will help with the development of more effective treatments. The researchers are also looking for biomarkers in blood tests to monitor the response of patients to treatment more accurately. Ultimately, their goal is to translate the research done in the laboratory to provide better care to patients with kidney cancer.

In about a third of patients who have surgery to remove their cancer, the cancer will eventually spread to other parts of their body (metastatic disease). To improve patient outcomes, the researchers need to better understand what causes this. They also want to understand why some patients are resistant to treatment.

Research is ongoing, but the clinical trial team feel it is important to share some of their work with patients, who they hope will benefit from this research one day.

Read the latest TRACERx patient-friendly newsletter here: TRACERx Renal 2023 Newsletter